

(μ_2 -ETHYLENDIAMINE-N,N,N',N'-TETRAACETATO)-{N-PHENYL-N'-[1-(PYRIDIN-2-YL)ETHYLYDENE]CARBAMOHDRAZONTHIOATOCUPPER(II)}-DI(AQUA)BISMUTH (III) TETRAHYDRATE WHICH SHOWS ANTIMYCOTIC ACTIVITY AGAINST *Candida albicans*


ACCEPTED PATENT APPLICATION: MD a 2022 0022 (DECISION no. 10337 of 2023.10.16)

AUTHORS: BULIMESTRU ION, NEGUȚA ELENA, NEGUȚA ANDREI, BĂLAN GRETA, LOZAN-TÎRȘU CAROLINA, ȚAPCOV VICTOR, GULEA AURELIAN

APPLICATION FIELDS: chemistry and medicine

AIM: extending the arsenal of inhibitors with high antimycotic activity against *Candida albicans* fungi

SOLUTION: A new heterometallic Cu(II)-Bi(III) coordination compound with high fungistatic activity against *Candida albicans* species.



The fungistatic activity ($\mu\text{g/mL}$) of the claimed compound against *Candida albicans* compared to fluconazole and the closest prior art

Compound	Minimum inhibition concentration
Fluconazole	15,62
N-cyclohexyl-2-[1-(pyridin-2-yl)ethylidene]hydrazinecarbothioamide (closest prior art)	0,7
(μ_2 -Ethylenediamine-N,N,N',N'-tetraacetato)-{N-phenyl-N'-[1-(pyridin-2-yl)ethylidene]carbamohydrazonthioato-copper(II)}-di(aqua)-bismuth(III) tetrahydrate (claimed compound)	0,49

ADVANTAGES: The claimed coordination compound exhibits 31.9 times higher activity than fluconazole and 1.4 times higher than the closest prior art.

IMPLEMENTATION STAGE: At the laboratory level

ACKNOWLEDGMENTS: This research was supported by the *research project: 20.80009.5007.10*